Volume 60, Issue 2, Pages (August 2001)

Slides:



Advertisements
Similar presentations
Kamyar Kalantar-Zadeh  Kidney International 
Advertisements

Acid-base profile in patients on PD
Nina Vasavada, Rajiv Agarwal  Kidney International 
Volume 66, Issue 6, Pages (December 2004)
Volume 54, Issue 2, Pages (August 1998)
Plasma sodium and hypertension
Buffer transport in peritoneal dialysis
Volume 70, Pages S138-S145 (November 2006)
Volume 82, Issue 1, Pages 7-8 (July 2012)
Giovanni Davogustto, MD, Thomas J. Wang, MD, Deepak K. Gupta, MD 
Acid-base profile in patients on PD
Use of icodextrin in high transport ultrafiltration failure
Volume 62, Issue 2, Pages (August 2002)
Volume 53, Issue 4, Pages (April 1998)
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
John M. Arthur, M.D.Ph.D., Shazia Shamim  Kidney International 
Ali K. Abu-Alfa, John Burkart, Beth Piraino, Joe Pulliam, Salim Mujais 
Volume 57, Issue 6, Pages (June 2000)
Volume 54, Issue 2, Pages (August 1998)
Volume 59, Issue 1, Pages (January 2001)
J-Shaped Mortality Relationship for Uric Acid in CKD
Kamyar Kalantar-Zadeh  Kidney International 
S.G. John, N.M. Selby, C.W. McIntyre  Kidney International 
Volume 76, Issue 3, Pages (August 2009)
V. La Milia, M. Limardo, G. Virga, M. Crepaldi, F. Locatelli 
N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment  Martina Franz, Wolfgang Woloszczuk, Walter.
What really happens to people on long-term peritoneal dialysis?
Volume 55, Issue 2, Pages (February 1999)
Volume 59, Issue 2, Pages (February 2001)
Volume 73, Pages S5-S17 (April 2008)
Pharmacokinetics of icodextrin in peritoneal dialysis patients
Volume 73, Pages S94-S101 (April 2008)
Volume 71, Issue 6, Pages (March 2007)
Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure  A. Parikova, W. Smit, D.G. Struijk,
Volume 68, Issue 2, Pages (August 2005)
Cardiac arrest and sudden death in dialysis units
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Nephrology Crossword: Peritoneal Dialysis
Volume 66, Issue 1, Pages (July 2004)
Future of icodextrin as an osmotic agent in peritoneal dialysis
Volume 60, Issue 6, Pages (December 2001)
The role of daily dialysis in the control of hyperphosphatemia
Profiling of peritoneal ultrafiltration
Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?  Peter Stenvinkel, Peter Barany, Olof Heimbürger, Roberto Pecoits-Filho,
Volume 59, Issue 6, Pages (June 2001)
Volume 65, Issue 1, Pages (January 2004)
Volume 63, Issue 2, Pages (February 2003)
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
The course of the remnant kidney model in mice
Nina Vasavada, Rajiv Agarwal  Kidney International 
Volume 64, Issue 2, Pages (August 2003)
Volume 63, Issue 1, Pages (January 2003)
Volume 80, Issue 10, Pages (November 2011)
Quantification of free water transport in peritoneal dialysis
Volume 70, Issue 3, Pages (August 2006)
Renal actions of synthetic Dendroaspis natriuretic peptide
Volume 61, Issue 2, Pages (February 2002)
Volume 65, Issue 1, Pages (January 2004)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 59, Issue 1, Pages (January 2001)
Volume 58, Issue 5, Pages (November 2000)
Volume 67, Issue 6, Pages (June 2005)
Volume 58, Issue 4, Pages (October 2000)
Volume 57, Issue 4, Pages (April 2000)
Volume 57, Issue 4, Pages (April 2000)
Volume 72, Issue 3, Pages (August 2007)
Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases  Martina Franz, Wolfgang Woloszczuk,
Gentamicin plasma and peritoneal dialysate concentrations in peritoneal dialysis patients with peritonitis. Gentamicin plasma and peritoneal dialysate.
Metabolic and laboratory effects of icodextrin
Presentation transcript:

Volume 60, Issue 2, Pages 513-519 (August 2001) Intraperitoneal atrial natriuretic peptide increases peritoneal fluid and solute removal  Tao Wang, Hui-Hong Cheng, Olof Heimbürger, Chi Chen, Jonas Bergström, Bengt Lindholm  Kidney International  Volume 60, Issue 2, Pages 513-519 (August 2001) DOI: 10.1046/j.1523-1755.2001.060002513.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Intraperitoneal volume versus dwell time. Symbols are: (▪) control group (N = 8); (○) low-dose atrial natriuretic peptide (ANP) group (N = 6); (⋄) high-dose ANP group (N = 6). Data are means ± SD. The intraperitoneal volume was significantly higher in the H-ANP group as compared to the two other groups (ANOVA repeated measurements). Kidney International 2001 60, 513-519DOI: (10.1046/j.1523-1755.2001.060002513.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 131I-human serum albumin (RISA) elimination rate from the peritoneal cavity. Abbreviations are: KE, total RISA elimination rate representing the fluid absorption rate from the peritoneal cavity; KEB, RISA elimination rate to the blood from the peritoneal cavity representing the peritoneal lymphatic absorption; KET, RISA elimination rate to the peritoneal tissue. Symbols are: (▪) control group; () low-dose ANP group; (□) high-dose ANP group. *Significant difference between the two other groups, P < 0.01. Kidney International 2001 60, 513-519DOI: (10.1046/j.1523-1755.2001.060002513.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Dialysate glucose concentration (D) to fresh dialysate glucose concentration (D0) ratio (A) and glucose concentration gradient (B) versus dwell time. Symbols are: (▪) control group (N = 8); (○) low-dose atrial natriuretic peptide (ANP) group (N = 6); (⋄) high-dose ANP group (N = 6). The D/D0 for glucose was significantly higher in the H-ANP group versus the L-ANP and control groups, P < 0.01. Otherwise there were no significant differences between groups. Kidney International 2001 60, 513-519DOI: (10.1046/j.1523-1755.2001.060002513.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Dialysate-to-plasma concentration ratio (D/P) for urea (A), sodium (B), potassium (C), and total protein (D) versus dwell time. Symbols are: (▪) control group (N = 8); (○) low-dose atrial natriuretic peptide (ANP) group (N = 6); (⋄) high-dose ANP group (N = 6). Differences between groups did not reach statistical significance, although the D/P for urea tended to be lower in the high-dose ANP group compared with the other two groups (P < 0.07, ANOVA repeated measurements. Kidney International 2001 60, 513-519DOI: (10.1046/j.1523-1755.2001.060002513.x) Copyright © 2001 International Society of Nephrology Terms and Conditions